Remestemcel-L + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mesenchymal Stromal Cells
Conditions
Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome, COVID
Trial Timeline
Apr 30, 2020 → Jan 2, 2022
NCT ID
NCT04371393About Remestemcel-L + Placebo
Remestemcel-L + Placebo is a phase 3 stage product being developed by Mesoblast for Mesenchymal Stromal Cells. The current trial status is terminated. This product is registered under clinical trial identifier NCT04371393. Target conditions include Mesenchymal Stromal Cells, Remestemcel-L, Acute Respiratory Distress Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04371393 | Phase 3 | Terminated |
Competing Products
1 competing product in Mesenchymal Stromal Cells
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PegLiposomal Doxorubicin + Carboplatin | Merck | Phase 2 | 52 |
Other Products from Mesoblast
Remestemcel-LPhase 3
72
Rexlemestrocel-L + HA mixture + SalinePhase 3
72
Infusion of one MPC expanded cord unit and one unexpanded cord unit + Infusion of two unexpanded cord blood units.Phase 3
72
Prochymal® + Placebo + Standard of Care for GVHDPhase 3
72
Placebo + PROCHYMAL adult human mesenchymal stem cellsPhase 3
72